• INVESTORS

                    Webcast
                    Q2 2023 TRACON Pharmaceuticals Inc Earnings Conference Call
                    08/05/20 4:30 PM EDT

                    TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. We are a leader in the field of endoglin biology and are using our expertise to develop antibodies that bind to the endoglin receptor. Our lead product candidate, TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the VEGF pathway. Our other product candidates are TRC205, an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. Each of our product candidates is expected to complement currently available therapies.

                    免费的ios翻外墙软件

                    免费的ios翻外墙软件

                    免费的ios翻外墙软件

                    • 08/03/20
                      Summary ToggleTRACON Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
                       老王安卓下载
                    • 07/29/20
                      Summary ToggleTRACON to Report Second Quarter 2023 Financial Results and Company Highlights on August 5, 2023
                       Printer Friendly
                    • 老王 v p n安卓版
                      老王加速最新版TRACON Pharmaceuticals Announces Filing of Protocol for ENVASARC Pivotal Trial with the FDA
                       Printer Friendly

                    免费的ios翻外墙软件

                    • 08/05/20 4:30 PM EDT

                      免费的ios翻外墙软件

                      老王加速app下载
                      Add to Google Calendar

                    免费的ios翻外墙软件

                    Sign up to receive email alerts whenever TRACON Pharmaceuticals Inc posts new information to the site. Just enter your email address and click Submit.

                    •  Print Page
                    •  RSS Feeds
                    •  Email Alerts
                    •  Contact